FDA Approves Breakthrough Therapy Designation for Investigational Drug for HIV Prevention
November 18th 2020The US Food and Drug Administration has granted breakthrough therapy designation for an investigational drug, a long-acting, injectable cabotegravir for HIV pre-exposure-prophylaxis (PrEP).
Read More